[vc_row][vc_column][vc_column_text] In August 2018, the FDA & European Commission announced the approval of Alnylam Pharmaceutical’s ONPATTRO, a first-of-its-kind RNA interference (RNAi) therapeutic. Evolution Executive’s latest […]
[vc_row][vc_column][vc_column_text] German pharmaceutical company Evotec has expanded its partnership with Scottish artificial intelligence drug design pioneers Exscientia, investing a further €15m in exchange for a minority […]
Pharmaceutical giants Pfizer are expanding their cancer portfolio through the $14B acquisition of California-based biopharmaceutical company Medivation. The acquisition follows two recent unsuccessful bids for Medivation […]
For our latest Data Visualisation project, the Evolution Global Team analysed historical new drug approval statistics and the current clinical trials pipeline to identify trends that […]